{
  "abstract": "Background: Resistance to immune checkpoint inhibitors and VEGFR‐targeted agents limits durable disease control in clear cell renal cell carcinoma (ccRCC). We examined a tumour cell proliferative transcriptional programme in relation to treatment response and progression‐free survival (PFS).\n\nMethods: We analysed predominantly unpaired baseline and progression single‐cell transcriptomes from anti‐PD‐1‐treated ccRCC. A fixed 20‐gene signature underwent patient‐adjusted pseudobulk and RNA‐inferred copy‐number analyses. Pretreatment scores were evaluated in 332 patients across four immunotherapy or sunitinib groups from three studies, with established proliferation benchmarks and time‐varying survival analyses.\n\nResults: The discovery comparison included five baseline and six progression patients. All 20 genes, including PLK1, UBE2C and CDC20, retained higher expression in the proliferative cluster after patient adjustment, although its abundance difference did not survive multiple‐testing correction (BH‐adjusted q = 0.164). The score closely tracked G2M (r = 0.915–0.980), without superior PFS discrimination in the primary benchmark. Inclusive response AUCs were 0.519 for IMmotion150 immunotherapy, 0.569 for IMmotion150 sunitinib and 0.693 for E‐MTAB‐3267. In E‐MTAB‐3267, the age‐ and sex‐adjusted HR was 1.54 per score standard deviation (95% CI 1.13–2.11). The IMmotion150 immunotherapy association weakened over follow‐up; excluding this nonproportional estimate yielded a pooled HR of 1.51 (95% CI 1.24–1.83) in 158 patients.\n\nConclusion: Single‐cell and bulk transcriptomic analyses connect a proliferative gene‐expression programme with adverse PFS during immunotherapy and sunitinib treatment in ccRCC. The signature provides a compact transcriptional readout of proliferation associated with treatment outcomes, with a stronger relationship to PFS than to objective response.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Urology Tianjin First Central Hospital Tianjin 300071 China tj-fch.com",
    "The First Central Clinical School Tianjin Medical University Tianjin 300071 China tijmu.edu.cn",
    "Department of Urology The First Affiliated Hospital of Xinxiang Medical University Weihui Henan 453100 China xxmu.edu.cn",
    "Tianjin First Central Hospital Nankai University Tianjin 300071 China nankai.edu.cn"
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 6,
  "authors": [
    {
      "affs": [
        0,
        1,
        2
      ],
      "name": "Zeyu Li",
      "orcid": "0009-0004-6819-7441"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Shaoqiang Xing"
    },
    {
      "affs": [
        0
      ],
      "name": "Sheng Zeng",
      "orcid": "0000-0002-6795-8024"
    },
    {
      "affs": [
        3
      ],
      "name": "Yifei Zhang"
    },
    {
      "affs": [
        1
      ],
      "name": "Yaowen Li",
      "orcid": "0000-0001-7472-6590"
    },
    {
      "affs": [
        0,
        1,
        3
      ],
      "name": "Qian Liu",
      "orcid": "0009-0003-8004-2517"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/c9cd5zmrk7ehc.bib",
  "cited_by": 0,
  "doi": "10.1155/genr/4050985",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13746105/",
  "id": "c9cd5zmrk7ehc",
  "issns": [
    "0016-6723",
    "1469-5073"
  ],
  "landing_url": "https://doi.org/10.1155/genr/4050985",
  "language": "en",
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Article"
    ],
    [
      "heading",
      "Research Article"
    ],
    [
      "openalex",
      "2730|Renal cell carcinoma treatment"
    ]
  ],
  "openalex": "W7225625117",
  "pdf_url": "https://onlinelibrary.wiley.com/doi/pdfdirect/10.1155/genr/4050985",
  "pmcid": "PMC13746105",
  "pmid": "43000998",
  "published": "2026-11-09",
  "publisher": "Wiley",
  "ris": "https://research.draconitic.com/paper/c9cd5zmrk7ehc.ris",
  "sources": [
    {
      "first_seen": "2026-11-11T12:23:33Z",
      "native_id": "PMC13746105",
      "source": "pmc",
      "url": "https://doi.org/10.1155/genr/4050985"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2730|Renal cell carcinoma treatment",
      "subfield": "oncology"
    }
  ],
  "title": "A Single‐Cell‐Derived Proliferative Signature Is Associated With Progression‐Free Survival During Immunotherapy and Sunitinib Treatment in Clear Cell Renal Cell Carcinoma",
  "title_text": "A Single‐Cell‐Derived Proliferative Signature Is Associated With Progression‐Free Survival During Immunotherapy and Sunitinib Treatment in Clear Cell Renal Cell Carcinoma",
  "type": "peer-reviewed",
  "updated_at": "2026-11-13T12:22:16Z",
  "url": "https://research.draconitic.com/paper/c9cd5zmrk7ehc",
  "venue": "Genetics Research",
  "versions": []
}